In March 2010, Cerep was granted, on behalf of its Chinese subsidiary Cerep Limited, the necessary Business License to operate in China.
The Company immediately launched its Asian operations, based in Shanghai, and successfully completed there its first pilot study. Through a panel of 71 kinase assays performed in parallel in Cerep’s French and Shanghai laboratories, the Company has demonstrated the homogeneity and quality of data obtained on the new platform. The objective of this first pilot was to validate that the technical fittings at the new site were capable of achieving quality levels equivalent to Cerep’s main laboratories, and therefore that the Company could now deliver to clients an equivalent level of services from its French, North American or Chinese operational facilities.
The laboratories, covering approximately 800m², were refitted over the past 6 months to rigorously comply with Cerep’s quality norms and operational standards.
They are located at the heart of a first rate technology park in which a large number of high tech companies, as well as many pharmaceutical companies, have already established themselves. Cerep is proud to be the first western laboratory establishing in China to operate an in vitro pharmacology platform dedicated to drug discovery.
The Group considers that setting up operations in this region was essential to better serve both Chinese companies as well as the subsidiaries of international groups operating in China. This gives Cerep a significant advantage in gaining entrance to new markets by meeting client needs where they originate, thus further developing the “satellite” strategy it started in 2009.
Cerep also considers that the growth of drug discovery outsourcing in China will intensify in the coming years, with the development of new Chinese players operating in this domain and the sustained growth of the Chinese operations of the world’s leading pharmaceutical companies.